Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 36 of the 67 sources its claims cite were checked for support.

TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity

Open access

Abstract

Lung macrophages play a pivotal role in pulmonary fibrosis, with monocyte-derived alveolar macrophages driving disease progression. However, the mechanisms regulating their pro-fibrotic behavior and survival remain unclear, and effective therapeutic strategies are lacking. Here we show that triggering receptors expressed on myeloid cells 2 are predominantly expressed on monocyte-derived alveolar macrophages in fibrotic mouse lungs and are significantly elevated in lung macrophages from patients with idiopathic pulmonary fibrosis. Deletion or knockdown of this receptor disrupts intracellular survival signaling, promotes macrophage apoptosis, and attenuates their pro-fibrotic phenotype. We further demonstrate that a lipid mediator and a high-avidity ligand of this receptor, encountered by macrophages in the alveolar milieu, enhance macrophage survival and activity. Ablation of TREM2 or blocking this receptor with soluble receptors or specific antibodies effectively alleviates lung fibrosis in male mice. These findings identify this receptor as a critical regulator of macrophage-mediated fibrosis and a promising therapeutic target for intervention. Monocyte-derived alveolar macrophages (Mo-AMs) are involved in lung injury and fibrosis through incompletely understood mechanisms. Here, the authors show that TREM2 is a critical regulator of lung fibrosis progression mediated by Mo-AMs and a potential target for therapeutic intervention.

Overview

CoChat Summary

## TL;DR

TREM2 is highly expressed on monocyte-derived alveolar macrophages in fibrotic mouse lungs and in IPF patient macrophages, where it promotes macrophage survival and pro-fibrotic activity. In mouse models, genetic deletion or pharmacologic blockade of TREM2 reduced bleomycin-induced lung fibrosis, while soluble TREM2 and a blocking antibody disrupted sphingomyelin-driven survival signaling.

## Key findings

  • In bleomycin-treated mouse lungs, TREM2 was markedly higher on Mo-AMs than on TR-AMs; in normal mouse lungs it was only moderate on AMs and classical monocytes, with little expression in other cells.
  • In human lungs, TREM2 was predominantly restricted to AMs and classical monocytes in normal tissue, and IPF lungs showed more macrophages with greater TREM2 expression; IPF AMs had markedly increased TREM2 versus normal lungs.
  • Global TREM2 KO mice had significantly decreased bleomycin-induced fibrosis, including lower lung hydroxyproline levels and diminished pro-fibrotic mediators.
  • Mo-AM-specific TREM2 deletion reduced fibrosis in bleomycin-treated mice, with reduced hydroxyproline, less trichrome-stained collagen, and lower micro-CT lung densities; in another model, Mo-AM TREM2(-/-) mice were also protected from TGF-β1-induced fibrosis.
  • TREM2 deficiency increased macrophage apoptosis and reduced pro-fibrotic genes/mediators, including lower SPP1, PDGFA, MMP12, and TGF-β1-related signals; TREM2-high macrophages in mouse and IPF lungs expressed more scar-associated and anti-apoptotic markers.
  • Sphingomyelin, elevated in BAL from bleomycin-injured mice, protected macrophages from apoptosis in a TREM2-dependent manner; sTREM2 and a TREM2-blocking antibody abolished this protection and attenuated lung fibrosis.

## Methods

  • Mouse and human study with bleomycin-induced lung fibrosis in mice, plus a second model using adenovirus expressing constitutively active TGF-β1; comparisons included global TREM2 KO mice and conditional Mo-AM TREM2 deletion mice.
  • Human samples came from IPF patients and failed-donor normal lungs; BAL-derived AMs and PBMC-derived macrophages were used for ex vivo assays, and published scRNA-seq datasets were reanalyzed.
  • Main analyses included flow cytometry, immunofluorescence, hydroxyproline assay, trichrome staining, micro-CT, apoptosis assays, ELISA, qPCR, Western blotting, lipidomics of BAL fluid, and ATII–Mo-AM alveolosphere co-culture.

## Limitations

  • The paper states that the underlying mechanism of TREM2’s intrinsic regulatory activity in macrophages “remains unclear.”
  • The authors note that the study’s anti-fibrotic effects were shown in male mice only, because “8–10 weeks male mice were used for all experiments.”
  • Evident from the text: much of the human evidence is observational (scRNA-seq reanalysis and microscopy), so it supports association rather than direct causal proof in patients.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-025-57024-0

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Mo-AMs demonstrate markedly higher expression of TREM2 than TR-AMs in the lungs of mice with bleomycin (BLM)-induced pulmonary fibrosis. A UMAP with TREM2 expression shown was re-produced from scRNA-seq dataset (lungendothelialcellatlas) on normal mouse lung. B Boxplots representing the average normalized TREM2 expression for each subject, grouped by cell type, was re-produced from dataset lungendothelialcellatlas. 25th and 75th percentiles (horizontal box edges), median (center line), minimum and maximum values (outer whiskers); each dot represents one subject; whiskers are 1.5x IQR. n = 29 mouse lungs. C 8 week male C57BL/6 mice were intratracheally (i.t.) instilled with saline or BLM (1.5 U/kg in 50 µl saline). Three weeks after treatment, lung sections were prepared and immunofluorescence staining was performed to determine the expression of TREM2 and F4/80. Scale bar: 100 µm. The experiment was repeated three times independently with similar results. D Mice were treated as in “C”. Bronchoalveolar lavages (BALs) were harvested and BAL cells stained with a cocktail of antibodies as detailed in Methods. TREM2 levels on F4/80 + / Siglec Fhigh/ CD11blow TR-AMs and F4/80 + / Siglec Flow/CD11bhigh Mo-AMs were determined by flow cytometric analysis. n = 3, 4, and 4 mice, respectively; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. MFI, mean fluorescence intensity. E Mice were i.t. instilled with BLM as in “C”. 6 days after treatment, BAL cells were harvested and stained with a cocktail of antibodies as detailed in Methods. Cell surface TREM2 levels on MERTK + /CD11blow TR-AMs, MERTK + /CD11high Mo-AMs, MERTK-/CD11b + /Ly-6G+ neutrophils and other BAL cells were determined by flow cytometric analysis. The experiments for “D, E” were repeated twice with similar results. Source data are provided as a Source Data file.
Fig. 1 Mo-AMs demonstrate markedly higher expression of TREM2 than TR-AMs in the lungs of mice with bleomycin (BLM)-induced pulmonary fibrosis. A UMAP with TREM2 expression shown was re-produced from scRNA-seq dataset (lungendothelialcellatlas) on normal mouse lung. B Boxplots representing the average normalized TREM2 expression for each subject, grouped by cell type, was re-produced from dataset lungendothelialcellatlas. 25th and 75th percentiles (horizontal box edges), median (center line), minimum and maximum values (outer whiskers); each dot represents one subject; whiskers are 1.5x IQR. n = 29 mouse lungs. C 8 week male C57BL/6 mice were intratracheally (i.t.) instilled with saline or BLM (1.5 U/kg in 50 µl saline). Three weeks after treatment, lung sections were prepared and immunofluorescence staining was performed to determine the expression of TREM2 and F4/80. Scale bar: 100 µm. The experiment was repeated three times independently with similar results. D Mice were treated as in “C”. Bronchoalveolar lavages (BALs) were harvested and BAL cells stained with a cocktail of antibodies as detailed in Methods. TREM2 levels on F4/80 + / Siglec Fhigh/ CD11blow TR-AMs and F4/80 + / Siglec Flow/CD11bhigh Mo-AMs were determined by flow cytometric analysis. n = 3, 4, and 4 mice, respectively; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. MFI, mean fluorescence intensity. E Mice were i.t. instilled with BLM as in “C”. 6 days after treatment, BAL cells were harvested and stained with a cocktail of antibodies as detailed in Methods. Cell surface TREM2 levels on MERTK + /CD11blow TR-AMs, MERTK + /CD11high Mo-AMs, MERTK-/CD11b + /Ly-6G+ neutrophils and other BAL cells were determined by flow cytometric analysis. The experiments for “D, E” were repeated twice with similar results. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 2 IPF AMs demonstrate considerably greater TREM2 expression than those from normal control lungs. A UMAP with TREM2 expression shown was re-produced from scRNA-seq dataset (GSE164829) on normal human lung. B Immunofluorescence staining was performed on human normal control and idiopathic pulmonary fibrosis (IPF) lung sections to determine the expression and localization of TREM2 and CD68. Scale bar: 100 µm. The experiment was repeated three times independently with similar results. C Boxplots representing the average normalized TREM2 expression for each subject, grouped by cell type, was re-produced from dataset GSE128033. 25th and 75th percentiles (horizontal box edges), median (center line), minimum and maximum values (outer whiskers); each dot represents one subject; whiskers are 1.5x IQR. n = 10 control (normal) lungs, n = 8 IPF lungs. CTRL, control (normal).
Fig. 2 IPF AMs demonstrate considerably greater TREM2 expression than those from normal control lungs. A UMAP with TREM2 expression shown was re-produced from scRNA-seq dataset (GSE164829) on normal human lung. B Immunofluorescence staining was performed on human normal control and idiopathic pulmonary fibrosis (IPF) lung sections to determine the expression and localization of TREM2 and CD68. Scale bar: 100 µm. The experiment was repeated three times independently with similar results. C Boxplots representing the average normalized TREM2 expression for each subject, grouped by cell type, was re-produced from dataset GSE128033. 25th and 75th percentiles (horizontal box edges), median (center line), minimum and maximum values (outer whiskers); each dot represents one subject; whiskers are 1.5x IQR. n = 10 control (normal) lungs, n = 8 IPF lungs. CTRL, control (normal).CC BY-NC-ND · PubMed Central
Fig. 3 Global TREM2 knockout, as well as conditional TREM2 knockout in Mo-AMs, protects mice from BLM-induced lung fibrosis. A Eight to ten week TREM2 wild-type (+/+) and TREM2 knockout (-/-) mice were i.t. instilled with saline or BLM (1.5 U/kg in 50 µl saline). Three weeks later, lung hydroxyproline levels were determined. n = 3, 3, 8, and 6 mice, respectively; mean ± SEM; *p < 0.05, one-way ANOVA with Turkey’s multiple comparisons test. B Total lung RNAs from the BLM treated mice in “A” were isolated and the expression of the indicated genes was determined by real-time PCR. mean ± SEM; unpaired two-tailed Student’s t-test. C Mo-AMs from the BLM treated mice in “A” were isolated by flow sorting and levels of TREM2 in the cells determined by real-time PCR. mean ± SEM; unpaired two-tailed Student’s t-test. D, E Eight to ten week Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were intraperitoneally (i.p.) injected with tamoxifen (75 mg/kg) for 5 consecutive days. 3 days later, the mice were i.t. instilled with saline or BLM (1.5 U/kg in 50 µl saline). The mice continued to receive tamoxifen injection, twice/week. 3 weeks after BLM treatment, Mo-AMs were isolated by flow sorting from the BLM treated mice and levels of TREM2 in the cells determined by real-time PCR (D). n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. The lungs in the above experiment were harvested and lung hydroxyproline levels were determined (E). n = 3, 3, 5, and 5 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. F Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were treated as in “D, E”. Lung sections were prepared and histological analysis performed by Masson’s trichrome staining. Scale bar: 500 µm. The experiment was repeated three times independently with similar results obtained. G Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were treated as in “D-F”. The severity of pulmonary fibrosis was assessed by noninvasive lung micro-CT scan. Representative axial micro-CT images of mouse lungs (gray scale or quad-prism color scale (blue to red represents low to high density)) and quantification of lung density (Hounsfield unit at the 85th percentile of the lung density) are shown. n = 3 mice per group; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Source data are provided as a Source Data file.
Fig. 3 Global TREM2 knockout, as well as conditional TREM2 knockout in Mo-AMs, protects mice from BLM-induced lung fibrosis. A Eight to ten week TREM2 wild-type (+/+) and TREM2 knockout (-/-) mice were i.t. instilled with saline or BLM (1.5 U/kg in 50 µl saline). Three weeks later, lung hydroxyproline levels were determined. n = 3, 3, 8, and 6 mice, respectively; mean ± SEM; *p < 0.05, one-way ANOVA with Turkey’s multiple comparisons test. B Total lung RNAs from the BLM treated mice in “A” were isolated and the expression of the indicated genes was determined by real-time PCR. mean ± SEM; unpaired two-tailed Student’s t-test. C Mo-AMs from the BLM treated mice in “A” were isolated by flow sorting and levels of TREM2 in the cells determined by real-time PCR. mean ± SEM; unpaired two-tailed Student’s t-test. D, E Eight to ten week Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were intraperitoneally (i.p.) injected with tamoxifen (75 mg/kg) for 5 consecutive days. 3 days later, the mice were i.t. instilled with saline or BLM (1.5 U/kg in 50 µl saline). The mice continued to receive tamoxifen injection, twice/week. 3 weeks after BLM treatment, Mo-AMs were isolated by flow sorting from the BLM treated mice and levels of TREM2 in the cells determined by real-time PCR (D). n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. The lungs in the above experiment were harvested and lung hydroxyproline levels were determined (E). n = 3, 3, 5, and 5 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. F Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were treated as in “D, E”. Lung sections were prepared and histological analysis performed by Masson’s trichrome staining. Scale bar: 500 µm. The experiment was repeated three times independently with similar results obtained. G Mo-AM TREM2 (+/+) and Mo-AM TREM2 (-/-) mice were treated as in “D-F”. The severity of pulmonary fibrosis was assessed by noninvasive lung micro-CT scan. Representative axial micro-CT images of mouse lungs (gray scale or quad-prism color scale (blue to red represents low to high density)) and quantification of lung density (Hounsfield unit at the 85th percentile of the lung density) are shown. n = 3 mice per group; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 4 TREM2 deficiency promotes apoptosis and diminishes pro-fibrotic gene expression in macrophages. A TREM2 (+/+) and TREM2 (-/-) Mo-AMs were isolated by flow sorting from mice that were treated BLM for 3 weeks, and apoptosis evaluated. n = 4 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. B Numbers of Mo-AMs in the BALs. n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. C BMDMs were transfected with control (con) and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. Cell apoptosis was determined 6 h after M-CSF withdrawal. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiment was repeated three with similar results. D BMDMs were transfected with control and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. Cells were harvested 6 h after M-CSF withdrawal and the expression of the indicated proteins were determined by Western blotting. The experiment was repeated three times with similar results. E The expression of pro-fibrotic mediators in Mo-AMs from mice treated in “A” was determined by real-time PCR. n = 4 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. F TGF-β1 levels in BALs from mice treated in “A” were determined by ELISA. n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. G BAL TGF-β1 levels in TREM2 (+/+) and TREM2 (-/-) mice instilled with saline or BLM for 3 weeks. n = 3, 3, 7, and 6 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. H, I Bubble plots for the indicated pro-fibrotic and anti-apoptotic genes in the macrophages from BLM treated mouse lungs (H) and human IPF lungs (I) were re-produced from scRNA-seq datasets GSE132771 (n = 2 mouse lungs) and GSE128033 (n = 5 IPF lungs), respectively. Source data are provided as a Source Data file.
Fig. 4 TREM2 deficiency promotes apoptosis and diminishes pro-fibrotic gene expression in macrophages. A TREM2 (+/+) and TREM2 (-/-) Mo-AMs were isolated by flow sorting from mice that were treated BLM for 3 weeks, and apoptosis evaluated. n = 4 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. B Numbers of Mo-AMs in the BALs. n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. C BMDMs were transfected with control (con) and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. Cell apoptosis was determined 6 h after M-CSF withdrawal. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiment was repeated three with similar results. D BMDMs were transfected with control and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. Cells were harvested 6 h after M-CSF withdrawal and the expression of the indicated proteins were determined by Western blotting. The experiment was repeated three times with similar results. E The expression of pro-fibrotic mediators in Mo-AMs from mice treated in “A” was determined by real-time PCR. n = 4 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. F TGF-β1 levels in BALs from mice treated in “A” were determined by ELISA. n = 6 and 5 mice, respectively; mean ± SEM; unpaired two-tailed Student’s t-test. G BAL TGF-β1 levels in TREM2 (+/+) and TREM2 (-/-) mice instilled with saline or BLM for 3 weeks. n = 3, 3, 7, and 6 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. H, I Bubble plots for the indicated pro-fibrotic and anti-apoptotic genes in the macrophages from BLM treated mouse lungs (H) and human IPF lungs (I) were re-produced from scRNA-seq datasets GSE132771 (n = 2 mouse lungs) and GSE128033 (n = 5 IPF lungs), respectively. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 5 Mo-AM TREM2 inhibits ATII regeneration and differentiation into ATI. A, B TREM2 (+/+) and TREM2 (-/-) Mo-AMs were isolated by flow sorting from mice treated with i.t. BLM for 1 week, respectively. The AMs were mixed with sorted ATIIs (5:1 ratio) in Matrigel and cultured for 12 days. ATII organoid number and size in each group were determined by ImageJ. n = 12 independent culture of cells per group; mean ± SD; unpaired two-tailed Student’s t-test. Scale bar: 2 mm. C–E ATII organoids from “A” were harvested and frozen sections prepared. Immunofluorescence microscopy was performed for the indicated proteins. Scale bar: 20 µm. All experiments were repeated twice with similar results obtained. Source data are provided as a Source Data file.
Fig. 5 Mo-AM TREM2 inhibits ATII regeneration and differentiation into ATI. A, B TREM2 (+/+) and TREM2 (-/-) Mo-AMs were isolated by flow sorting from mice treated with i.t. BLM for 1 week, respectively. The AMs were mixed with sorted ATIIs (5:1 ratio) in Matrigel and cultured for 12 days. ATII organoid number and size in each group were determined by ImageJ. n = 12 independent culture of cells per group; mean ± SD; unpaired two-tailed Student’s t-test. Scale bar: 2 mm. C–E ATII organoids from “A” were harvested and frozen sections prepared. Immunofluorescence microscopy was performed for the indicated proteins. Scale bar: 20 µm. All experiments were repeated twice with similar results obtained. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 6 Sphingomyelin (SM) protects macrophages from apoptosis. A–D C57BL/6 mice were i.t. instilled with BLM. At 0, 1, 2, and 4 weeks post-treatment, BALs were collected and lipidomics was performed. A PCA analysis shows segregation of BALF samples based on groups. B–D The levels of various forms of sphingomyelins in the BALs. The box-and-whisker plots depict the 25th and 75th percentiles (horizontal box edges), median (center line), mean (+), minimum and maximum values (outer whiskers), and outliers (dots outside the whiskers). n = 6 mice per group; one-way ANOVA with Bonferroni’s multiple comparisons test. E BMDMs were cultured in the absence or presence of 10 ng/ml M-CSF, and treated with or without 10 µg/ml SM for 6 h. Cell apoptosis was determined. The average luminescent intensity in the control group ( + M-CSF, -SM) was regarded as “1”. The intensity of other groups to the control group was shown as fold change. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. F Experiments were done as in “E”. The expression of the indicated protein was determined by Western blotting. G BMDMs were treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. H BMDMs were transfected with control and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. The cells were then treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. I TREM2 (+/+) and TREM2 (-/-) BMDMs were treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. J TREM2 (+/+) and TREM2 (-/-) BMDMs were cultured in the absence or presence of 10 ng/ml M-CSF, and treated with or without 10 µg/ml SM for 6 h. Cell apoptosis was determined. The average luminescent intensity in the control group (fl/fl +M-CSF, -SM) was regarded as “1”. The intensity of other groups to the control group was shown as fold change. n = 4 independent culture of cells; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiments for “E–J” were repeated three times with similar results. Source data are provided as a Source Data file.
Fig. 6 Sphingomyelin (SM) protects macrophages from apoptosis. A–D C57BL/6 mice were i.t. instilled with BLM. At 0, 1, 2, and 4 weeks post-treatment, BALs were collected and lipidomics was performed. A PCA analysis shows segregation of BALF samples based on groups. B–D The levels of various forms of sphingomyelins in the BALs. The box-and-whisker plots depict the 25th and 75th percentiles (horizontal box edges), median (center line), mean (+), minimum and maximum values (outer whiskers), and outliers (dots outside the whiskers). n = 6 mice per group; one-way ANOVA with Bonferroni’s multiple comparisons test. E BMDMs were cultured in the absence or presence of 10 ng/ml M-CSF, and treated with or without 10 µg/ml SM for 6 h. Cell apoptosis was determined. The average luminescent intensity in the control group ( + M-CSF, -SM) was regarded as “1”. The intensity of other groups to the control group was shown as fold change. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. F Experiments were done as in “E”. The expression of the indicated protein was determined by Western blotting. G BMDMs were treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. H BMDMs were transfected with control and TREM2 siRNAs and then cultured in the presence of 10 ng/ml M-CSF for 2 days. The cells were then treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. I TREM2 (+/+) and TREM2 (-/-) BMDMs were treated with or without 10 µg/ml SM in the absence of M-CSF for 6 h. The expression of the indicated protein was determined by Western blotting. J TREM2 (+/+) and TREM2 (-/-) BMDMs were cultured in the absence or presence of 10 ng/ml M-CSF, and treated with or without 10 µg/ml SM for 6 h. Cell apoptosis was determined. The average luminescent intensity in the control group (fl/fl +M-CSF, -SM) was regarded as “1”. The intensity of other groups to the control group was shown as fold change. n = 4 independent culture of cells; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiments for “E–J” were repeated three times with similar results. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 7 sTREM2 blunts the protective activity of sphingomyelin on macrophage survival and alleviates BLM-induced lung fibrosis. A BMDMs were treated with vehicle, 10 μg/ml SM, or 10 μg/ml SM that was pre-incubated with 2.5 µg/ml mouse sTREM2, for 6 h in the absence of M-CSF. The levels of the indicated proteins were determined by Western blotting. The experiment was repeated three times with similar results. B Plated Mo-AMs were treated with SM (5 µg/ml), pre-incubated for 1 h with vehicle or 4 μg/ml mouse sTREM2, for 2 days and apoptosis determined. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiment was repeated twice times with similar results. C, D Eight week C57BL/6 mice were i.t. instilled with saline or BLM (1.5 U/kg). One week later, mice were administered vehicle or sTREM2 (65 μg/kg), once a day for 8 days. 3 weeks after BLM treatment, lungs and BALs were collected, and whole lung hydroxyproline (C) and BAL TREM2 protein levels (D) were determined. n = 3, 5, and 5 mice, respectively for “C”; n = 3, 5, and 4 mice, respectively for “D”; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Source data are provided as a Source Data file.
Fig. 7 sTREM2 blunts the protective activity of sphingomyelin on macrophage survival and alleviates BLM-induced lung fibrosis. A BMDMs were treated with vehicle, 10 μg/ml SM, or 10 μg/ml SM that was pre-incubated with 2.5 µg/ml mouse sTREM2, for 6 h in the absence of M-CSF. The levels of the indicated proteins were determined by Western blotting. The experiment was repeated three times with similar results. B Plated Mo-AMs were treated with SM (5 µg/ml), pre-incubated for 1 h with vehicle or 4 μg/ml mouse sTREM2, for 2 days and apoptosis determined. n = 4 independent culture of cells per group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. The experiment was repeated twice times with similar results. C, D Eight week C57BL/6 mice were i.t. instilled with saline or BLM (1.5 U/kg). One week later, mice were administered vehicle or sTREM2 (65 μg/kg), once a day for 8 days. 3 weeks after BLM treatment, lungs and BALs were collected, and whole lung hydroxyproline (C) and BAL TREM2 protein levels (D) were determined. n = 3, 5, and 5 mice, respectively for “C”; n = 3, 5, and 4 mice, respectively for “D”; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central
Fig. 8 TREM2 blocking antibody abolishes the protective effect of SM and attenuates lung fibrosis in BLM-treated mice. A, B TREM2 (+/+) or (-/-) Mo-AMs were pre-treated for 1 h with control (con Ab) or TREM2 blocking antibody (TREM2 Ab) (4 μg/ml), followed by incubation with SM (5 μg/ml) for 2 days and apoptosis determined. n = 3, 4, 4 (for “A”) and n = 4 (for “B”) independent culture of cells for each group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. n.s., non-significant. Experiments were repeated twice times with similar results. C–E Eight week C57BL/6 mice were i.t. instilled with saline or BLM (1.5 U/kg). One day later, mice were administered i.p. with control antibody (200 µg/mouse) or the TREM2 blocking antibody (200 µg/mouse), once every five days for a total of 4 times. Three weeks after BLM treatment, lungs were collected and whole lung hydroxyproline levels were determined (C). n = 3, 6, and 6 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Mo-AMs from the BLM treated mice were flow sorted (D). n = 6 mice per group; mean ± SEM; TGF-β1 in the BALs from the BLM treated mice was determined (E). n = 6 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. Source data are provided as a Source Data file.
Fig. 8 TREM2 blocking antibody abolishes the protective effect of SM and attenuates lung fibrosis in BLM-treated mice. A, B TREM2 (+/+) or (-/-) Mo-AMs were pre-treated for 1 h with control (con Ab) or TREM2 blocking antibody (TREM2 Ab) (4 μg/ml), followed by incubation with SM (5 μg/ml) for 2 days and apoptosis determined. n = 3, 4, 4 (for “A”) and n = 4 (for “B”) independent culture of cells for each group; mean ± SD; one-way ANOVA with Bonferroni’s multiple comparisons test. n.s., non-significant. Experiments were repeated twice times with similar results. C–E Eight week C57BL/6 mice were i.t. instilled with saline or BLM (1.5 U/kg). One day later, mice were administered i.p. with control antibody (200 µg/mouse) or the TREM2 blocking antibody (200 µg/mouse), once every five days for a total of 4 times. Three weeks after BLM treatment, lungs were collected and whole lung hydroxyproline levels were determined (C). n = 3, 6, and 6 mice, respectively; mean ± SEM; one-way ANOVA with Bonferroni’s multiple comparisons test. Mo-AMs from the BLM treated mice were flow sorted (D). n = 6 mice per group; mean ± SEM; TGF-β1 in the BALs from the BLM treated mice was determined (E). n = 6 mice per group; mean ± SEM; unpaired two-tailed Student’s t-test. Source data are provided as a Source Data file.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

15 Valid · 0 Not valid · 4 Not checked · 83 Own results and interpretations

65 more claims

Create a free account to see all 102 claims and to verify the 8 references still open.

See all claims — free account
  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 63 references

Cited by

See all 74

Metadata

Authors
Cui, H., Banerjee, S., Xie, N., Hussain, M., Jaiswal, A., Liu, H., Kulkarni, T., Antony, V. B., Liu, R.-M., Colonna, M., & Liu, G.
Affiliations
  • University of Alabama at Birmingham (US)
  • Washington University in St. Louis (US)
Corresponding author
Liu, Gang
Venue
Nature Communications
Published
2025-02-19
Volume
16
Issue
1
Pages
1761-1761
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4407745349
Cited by
74
References
63
Citations by year
2026: 63 · 2025: 11
FWCI
48.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health & Human Services | National Institutes of Health (R35HL135830, R01AI170913)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
TREM2, pulmonary fibrosis, idiopathic pulmonary fibrosis, alveolar macrophages, macrophage survival, macrophage apoptosis, therapeutic target
MeSH terms
Animals, Cell Survival, Female, Humans, Lung, Male, Membrane Glycoproteins, Mice, Inbred C57BL, Pulmonary Fibrosis, Receptors, Immunologic, Signal Transduction, Macrophages, Alveolar, Apoptosis, Mice, Knockout, Mice, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. https://app.cochat.ai/papers/10.1038/s41467-025-57024-0
The paper
Cui, H., Banerjee, S., Xie, N., Hussain, M., Jaiswal, A., Liu, H., Kulkarni, T., Antony, V. B., Liu, R.-M., Colonna, M., & Liu, G. (2025). TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nature Communications. https://doi.org/10.1038/s41467-025-57024-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.